These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33653952)

  • 21. Nucleation precursors in protein crystallization.
    Vekilov PG; Vorontsova MA
    Acta Crystallogr F Struct Biol Commun; 2014 Mar; 70(Pt 3):271-82. PubMed ID: 24598910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of the p53 transactivation domain results in high amyloid aggregation of the Δ40p53 isoform in endometrial carcinoma cells.
    Melo Dos Santos N; de Oliveira GAP; Ramos Rocha M; Pedrote MM; Diniz da Silva Ferretti G; Pereira Rangel L; Morgado-Diaz JA; Silva JL; Rodrigues Pereira Gimba E
    J Biol Chem; 2019 Jun; 294(24):9430-9439. PubMed ID: 31028175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncogenic gain of function due to p53 amyloids occurs through aberrant alteration of cell cycle and proliferation.
    Navalkar A; Paul A; Sakunthala A; Pandey S; Dey AK; Saha S; Sahoo S; Jolly MK; Maiti TK; Maji SK
    J Cell Sci; 2022 Aug; 135(15):. PubMed ID: 35796018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p53 amyloid formation leading to its loss of function: implications in cancer pathogenesis.
    Ghosh S; Salot S; Sengupta S; Navalkar A; Ghosh D; Jacob R; Das S; Kumar R; Jha NN; Sahay S; Mehra S; Mohite GM; Ghosh SK; Kombrabail M; Krishnamoorthy G; Chaudhari P; Maji SK
    Cell Death Differ; 2017 Oct; 24(10):1784-1798. PubMed ID: 28644435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biophysical characterization of p53 core domain aggregates.
    Lima I; Navalkar A; Maji SK; Silva JL; de Oliveira GAP; Cino EA
    Biochem J; 2020 Jan; 477(1):111-120. PubMed ID: 31841126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Biomolecular Condensation and Protein Aggregation against Cancer.
    Silva JL; Foguel D; Ferreira VF; Vieira TCRG; Marques MA; Ferretti GDS; Outeiro TF; Cordeiro Y; de Oliveira GAP
    Chem Rev; 2023 Jul; 123(14):9094-9138. PubMed ID: 37379327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition.
    Wilcken R; Wang G; Boeckler FM; Fersht AR
    Proc Natl Acad Sci U S A; 2012 Aug; 109(34):13584-9. PubMed ID: 22869713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elucidating the Mechanisms of R248Q Mutation-Enhanced p53 Aggregation and Its Inhibition by Resveratrol.
    Liu Q; Li L; Yu Y; Wei G
    J Phys Chem B; 2023 Sep; 127(36):7708-7720. PubMed ID: 37665658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
    Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
    Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prion-like aggregation of mutant p53 in cancer.
    Silva JL; De Moura Gallo CV; Costa DC; Rangel LP
    Trends Biochem Sci; 2014 Jun; 39(6):260-7. PubMed ID: 24775734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Soluble TREM2 inhibits secondary nucleation of Aβ fibrillization and enhances cellular uptake of fibrillar Aβ.
    Belsare KD; Wu H; Mondal D; Bond A; Castillo E; Jin J; Jo H; Roush AE; Pilla KB; Sali A; Condello C; DeGrado WF
    Proc Natl Acad Sci U S A; 2022 Feb; 119(5):. PubMed ID: 35082148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights.
    Merabet A; Houlleberghs H; Maclagan K; Akanho E; Bui TT; Pagano B; Drake AF; Fraternali F; Nikolova PV
    Biochem J; 2010 Mar; 427(2):225-36. PubMed ID: 20113312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crucial role of nonspecific interactions in amyloid nucleation.
    Šarić A; Chebaro YC; Knowles TP; Frenkel D
    Proc Natl Acad Sci U S A; 2014 Dec; 111(50):17869-74. PubMed ID: 25453085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. R248Q mutation--Beyond p53-DNA binding.
    Ng JW; Lama D; Lukman S; Lane DP; Verma CS; Sim AY
    Proteins; 2015 Dec; 83(12):2240-50. PubMed ID: 26442703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer.
    Silva JL; Cino EA; Soares IN; Ferreira VF; A P de Oliveira G
    Acc Chem Res; 2018 Jan; 51(1):181-190. PubMed ID: 29260852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutational analysis of the p53 core domain L1 loop.
    Zupnick A; Prives C
    J Biol Chem; 2006 Jul; 281(29):20464-73. PubMed ID: 16687402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer-Associated Mutations Perturb the Disordered Ensemble and Interactions of the Intrinsically Disordered p53 Transactivation Domain.
    Schrag LG; Liu X; Thevarajan I; Prakash O; Zolkiewski M; Chen J
    J Mol Biol; 2021 Jul; 433(15):167048. PubMed ID: 33984364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of Dependence of the Sizes of the Mesoscopic Protein Clusters on Electrostatics.
    Vorontsova MA; Chan HY; Lubchenko V; Vekilov PG
    Biophys J; 2015 Nov; 109(9):1959-68. PubMed ID: 26536272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Advances on mutant p53 research].
    Li DH; Zhang LQ; He FC
    Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase separation of p53 induced by its unstructured basic region and prevented by oncogenic mutations in tetramerization domain.
    Chen C; Fu G; Guo Q; Xue S; Luo SZ
    Int J Biol Macromol; 2022 Dec; 222(Pt A):207-216. PubMed ID: 36108750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.